Millie
your market intelligence analyst
Search Results
Edit Save
180 results
Hoffmann-La Roche (EU) 10/16/2019 01:00
Group sales increase 10% at constant exchange rates and 9% in Swiss francs, due to new products. Pharmaceuticals Division sales up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta. Diagnostics Division sales grow 4%, primarily due to its immunodiagnostic testing portfolio.
Hoffmann-La Roche (EU) 10/15/2019 04:00
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 12 November 2019, highlighting Roche data in lupus nephritis presented at the American Society of Nephrology (7 - 10 Nov) as well as the American College of Rheumatology Annual Meetings (8 - 13 Nov) in Washington, DC and Atlanta, United States, respectively.
Hoffmann-La Roche (EU) 09/30/2019 02:30
Roche will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next generation sequencing (NGS) to detect specific fusions with the aim of selecting treatment for people with advanced non-small cell lung cancer (NSCLC), without the need for tissue biopsy.
Hoffmann-La Roche (EU) 09/30/2019 01:00
Roche and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the "Offer").
Hoffmann-La Roche (EU) 09/28/2019 01:00
Roche will present new data at the European Society for Medical Oncology (ESMO) 2019 congress, announcing the results of a number of studies in patients receiving Alecensa® (alectinib) for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Hoffmann-La Roche (EU) 09/27/2019 10:00
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).
Hoffmann-La Roche (EU) 09/27/2019 08:00
Roche will today present results from a Phase Ib study evaluating the efficacy and safety of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, who have not received prior systemic therapy.
Hoffmann-La Roche (EU) 09/06/2019 01:03
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Hoffmann-La Roche (EU) 08/29/2019 01:03
Roche today announced the expanded use of the VENTANA PD-L1 (SP142) Assay in triple-negative breast cancer (TNBC) for patients living in CE (Conformité Européene) markets where the Roche cancer immunotherapy medicine Tecentriq® is approved.
Hoffmann-La Roche (EU) 08/29/2019 01:00
Roche today announced that the European Commission has approved Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression (≥1%) and who have not received prior chemotherapy for metastatic disease.

Financial Services

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Political Entities

Sources

Strategic Scenarios

Trends

Hints:

  • Actions
    • Bookmark and Share: Allows you to Bookmark the page for easy future retrieval and sharing with colleagues
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Save" button to the right of the search box. 

Click here for more info on Search Results.